Table 4:
Univariate analysis testing the covariates associated with MACE among those with a CUD with HF
| Hazard ratio | 95% CI | p-value | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Gender | 1.123 | 0.821 | 1.723 | 0.381 |
| Age | 1.079 | 0.923 | 1.286 | 0.283 |
| BMI (kg/m2) | 0.959 | 0.755 | 1.117 | 0.241 |
| Diabetes | 1.351 | 0.837 | 2.119 | 0.477 |
| Hypertension | 1.068 | 0.682 | 1.844 | 0.724 |
| H/o CAD | 1.371 | 1.187 | 1.511 | <0.001* |
| LVEF (%) | 0.775 | 0.629 | 0.973 | 0.008* |
| PASP (mmHg) | 1.224 | 1.046 | 1.464 | 0.003* |
| NT-proBNP (pg/mL) | 1.432 | 1.044 | 3.028 | 0.004* |
| SBP (mmHg) | 1.132 | 0.722 | 1.778 | 0.632 |
| DBP (mmHg) | 1.088 | 0.668 | 1.622 | 0.602 |
| HR (bpm) | 1.111 | 0.833 | 1.571 | 0.433 |
| QRS duration (ms) | 1.154 | 1.036 | 1.942 | 0.021 |
| QTc duration (ms) | 1.083 | 1.007 | 1.841 | 0.013 |
| SA | 1.122 | 0.614 | 1.354 | 0.806 |
| Education (GED completion) | 0.722 | 0.443 | 0.927 | 0.006* |
| Unemployment | 1.178 | 1.010 | 1.898 | 0.009* |
| Carvedilol | 0.722 | 0.552 | 0.924 | 0.006* |
| ACE-I/ARB | 0.865 | 0.441 | 0.824 | 0.008* |
| Spironolactone | 1.109 | 0.823 | 1.563 | 0.716 |
| Furosemide | 1.271 | 0.755 | 2.223 | 0.543 |
*
p<0.01,
CAD= coronary artery disease, SA= sleep apnea, CAD= coronary artery disease, ACE I= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, LVEF= left ventricular ejection fraction, PASP= pulmonary artery systolic pressure, BMI= body mass index.
NT-proBNP= log transformed